Benefits:

- Exosome-based treatment is less likely to produce an immunogenic response, while also not inhibited by immunosuppressive environments
- MiR-186 is a broad-acting tumor suppressor (several malignancies)
- Exosomes are bioactive even when derived from inactive NK cells
- Myc amplified cancers comprise a wide range of cancers far beyond neuroblastoma
- TGF-β signaling is also frequently deregulated in late stage cancer

Applications:

- Targeted therapy for potentially any tumor driven by Myc, AURKA, or TGF-β